Mycenax Biotech (4726) — Financial Flexibility Index
Mycenax Biotech (4726) has a Financial Flexibility Index of -0.02x as of September 2025. Free cash flow of NT$-25.73 Million (operating CF NT$-50.35 Million minus capex NT$24.62 Million) represents 0% of total liabilities (NT$1.69 Billion). Check Mycenax Biotech strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Mycenax Biotech Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for Mycenax Biotech across 8 annual periods. See 4726 working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Mycenax Biotech (2017–2024)
Year-by-year free cash flow to debt coverage for Mycenax Biotech. For the full company profile including market capitalisation, see market cap of Mycenax Biotech.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.10x | NT$138.83 Million | NT$-191.68 Million | NT$1.34 Billion | ▼ -17.9% |
| 2023 | 0.13x | NT$166.42 Million | NT$-131.18 Million | NT$1.32 Billion | ▼ -64.5% |
| 2022 | 0.35x | NT$476.75 Million | NT$-150.19 Million | NT$1.35 Billion | ▼ -54.2% |
| 2021 | 0.77x | NT$951.86 Million | NT$-146.23 Million | NT$1.23 Billion | ▼ -3.8% |
| 2020 | 0.80x | NT$434.39 Million | NT$174.17 Million | NT$540.89 Million | ▲ +561.3% |
| 2019 | 0.12x | NT$37.17 Million | NT$-140.74 Million | NT$306.04 Million | ▲ +141.6% |
| 2018 | -0.29x | NT$-61.79 Million | NT$-180.27 Million | NT$211.70 Million | ▼ -207.3% |
| 2017 | 0.27x | NT$45.96 Million | NT$-45.55 Million | NT$168.93 Million | — |